Athira Pharma Inc expected to post a loss of 67 cents a share - Earnings Preview

LeonaBio

20/03/2023 20:48

* Athira Pharma Inc  ATHA.OQ   ATHA.O  is expected to show
no
change in quarterly revenue when it reports  results on March 22
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Athira Pharma Inc
is for
a loss of 67 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Athira
Pharma Inc
is $5.5​, above​ its last closing price of $2.58. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.65       -0.63      -0.53     Beat    16.3
 Jun. 30 2022  -0.64       -0.64      -0.65     Missed  -1.8
 Mar. 31 2022  -0.53       -0.55      -0.56     Missed  -1.8​
 Dec. 31 2021  -0.44       -0.54      -0.45     Beat    16.7
 ​​Sep.        -0.50       -0.50      -0.42     Beat    15.4
 30 2021                                                
 Jun. 30 2021  -0.38       -0.34      -0.38     Missed  -10.1​
 Mar. 31 2021  -0.30       -0.30      -0.25     Beat    17.4
 Dec. 31 2020              -0.40      -0.24     Beat    39.5
 This summary was machine generated March 20 at 20:48 GMT.  All
figures in US dollars  unless otherwise stated